Melanoma Clinical Trial
Official title:
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02C
| Verified date | January 2024 |
| Source | Merck Sharp & Dohme LLC |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Substudy 02C is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02C is to evaluate the safety and efficacy of investigational treatment arms in participants with Stage III melanoma who are candidates for neoadjuvant therapy to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. Arm 1: Pembrolizumab + Vibostolimab, Arm 2: Pembrolizumab + Gebasaxturev, and Arm 3: Pembrolizumab were added in the base protocol on 13-Nov-2019, and enrollment into those arms has been completed. Arm 4: Pembrolizumab + MK-4830 was added in Amendment 04 on 20-Dec-2021, and enrollment into that arm has been completed. Arm 5: Favezelimab + Pembrolizumab and Arm 6: Pembrolizumab + all-trans retinoic acid (ATRA) were added in Amendment 06 on 25-Jun-2022, and enrollment is ongoing.
| Status | Active, not recruiting |
| Enrollment | 90 |
| Est. completion date | April 3, 2030 |
| Est. primary completion date | April 3, 2030 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 120 Years |
| Eligibility | Inclusion Criteria: - Has histologically or cytologically confirmed melanoma - Has clinically detectable and resectable Stage IIIB or IIIC or IIID melanoma amenable to surgery - Has been untreated for Stage IIIB, IIIC or IIID melanoma - surgical resection of primary melanoma is allowed - prior radiotherapy to the primary melanoma is allowed - Has provided a baseline tumor biopsy - Male participants who receive gebasaxturev are abstinent from heterosexual intercourse or agree to use contraception during the intervention period and for at least 120 days after the last dose of gebasaxturev - Male participants who receive ATRA are abstinent from heterosexual intercourse or agree to use contraception during the intervention period and for at least 7 days after the last dose of ATRA - Female participants are not pregnant or breastfeeding and are either not a woman of child-bearing potential (WOCBP) OR use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after the last dose of pembrolizumab, vibostolimab, gebasaxturev, or MK-4830, favezelimab + pembrolizumab, or 30 days after the last dose of ATRA, whichever occurs last - Has adequate organ function - Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia) Exclusion Criteria: - Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within 7 days before the first dose of study intervention - Has a known additional malignancy that is progressing or requires active treatment within the past 2 years - Has known central nervous system (CNS) metastases and/or carcinomatous meningitis - Has ocular or mucosal melanoma - Has known hypersensitivity including previous clinically significant hypersensitivity reaction to treatment with another monoclonal antibody (mAb) - Has an active autoimmune disease that has required systemic treatment in the past 2 years - Has an active infection requiring systemic therapy - Has known history of human immunodeficiency virus (HIV) - Has known history of hepatitis B - Has a history of (noninfectious) pneumonitis - Has a history of active tuberculosis (TB) - Has received prior systemic anticancer therapy within 4 weeks prior to randomization - Has received prior radiotherapy within 2 weeks of first dose of study intervention - Has had major surgery <3 weeks prior to first dose of study intervention - Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention - Has participated in a study of an investigational agent within 4 weeks prior to the first dose of study intervention - Has had an allogeneic tissue/solid organ transplant - Has only mucosal lesions - Is not naïve to Talimogene laherparepvec (TVEC) and other oncolytic viruses |
| Country | Name | City | State |
|---|---|---|---|
| Australia | Fiona Stanley Hospital ( Site 3401) | Murdoch | Western Australia |
| Australia | Tasman Oncology Research Pty Ltd ( Site 3403) | Southport | Queensland |
| Australia | Melanoma Institute Australia ( Site 3402) | Wollstonecraft | New South Wales |
| France | Hopital La Timone ( Site 3103) | Marseille | Bouches-du-Rhone |
| France | A.P.H. Paris, Hopital Saint Louis ( Site 3107) | Paris | |
| France | Centre Hospitalier Lyon Sud ( Site 3102) | Pierre Benite | Rhone |
| France | Institut Claudius Regaud ( Site 3105) | Toulouse cedex 9 | Haute-Garonne |
| France | Gustave Roussy ( Site 3101) | Villejuif | Ile-de-France |
| Israel | HaEmek Medical Center ( Site 3703) | Afula | |
| Israel | Rambam Health Care Campus-Oncology ( Site 3704) | Haifa | |
| Israel | Hadassah Ein Karem Jerusalem ( Site 3702) | Jerusalem | |
| Israel | Rabin Medical Center-Oncology ( Site 3705) | Petah-Tikva | |
| Israel | Chaim Sheba Medical Center ( Site 3701) | Ramat Gan | |
| Italy | Istituto Europeo di Oncologia ( Site 3301) | Milano | |
| Italy | Policlinico Le Scotte - A.O. Senese ( Site 3377) | Siena | |
| Switzerland | Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 3603) | Genève | Geneve |
| Switzerland | CHUV Centre Hospitalier Universitaire Vaudois ( Site 3602) | Lausanne | Vaud |
| Switzerland | Universitaetsspital Zuerich ( Site 3601) | Zuerich Flughafen | Zurich |
| United States | University of Colorado, Anschutz Cancer Pavilion ( Site 3012) | Aurora | Colorado |
| United States | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 3022) | Baltimore | Maryland |
| United States | Martha Morehouse Tower ( Site 3020) | Columbus | Ohio |
| United States | Duke Cancer Institute ( Site 3005) | Durham | North Carolina |
| United States | Inova Schar Cancer Institute ( Site 3011) | Fairfax | Virginia |
| United States | West Cancer Center - East Campus ( Site 3014) | Germantown | Tennessee |
| United States | The Angeles Clinic and Research Institute ( Site 3009) | Los Angeles | California |
| United States | NYU Clinical Cancer Center ( Site 3002) | New York | New York |
| United States | University of Pennsylvania Abramson Cancer Center ( Site 3008) | Philadelphia | Pennsylvania |
| United States | Oregon Health & Science University ( Site 3013) | Portland | Oregon |
| United States | Providence Saint John's Health Center ( Site 3010) | Santa Monica | California |
| Lead Sponsor | Collaborator |
|---|---|
| Merck Sharp & Dohme LLC |
United States, Australia, France, Israel, Italy, Switzerland,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of participants who experience an adverse event (AE) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experience an AE will be reported. | Up to ~16 months | |
| Primary | Percentage of participants who discontinue study treatment due to an AE | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study treatment due to an AE will be reported. | Up to ~12 months | |
| Primary | Pathological complete response (pCR) rate | pCR rate is defined as the proportion of participants with complete absence of viable tumor in the treated tumor bed. Assessments are according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by central review of the pathology results. RECIST 1.1 has been modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. | Up to ~1.5 months | |
| Secondary | Near pathological complete response (near pCR) rate | Near pCR is defined as the proportion of participants with >0% but =10% of viable tumor cells in the treated tumor bed. Assessments are according to RECIST 1.1 by central review of the pathology results. RECIST 1.1 has been modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. | Up to ~1.5 months | |
| Secondary | Pathological partial response (pPR) rate | pPR rate is defined as the proportion of participants with >10% but =50% of the treated tumor bed occupied by viable tumor cells. Assessments are according to RECIST 1.1 by central review of the pathology results. RECIST 1.1 has been modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. | Up to ~1.5 months | |
| Secondary | Recurrence-free survival (RFS) | RFS is defined as the time from the date of surgery to (1) any recurrence (local, regional, or distant) as assessed by the investigator or (2) death due to any cause (both cancer and noncancer causes of death). Assessments are according to RECIST 1.1 which has been modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. | Up to ~60 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
| Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
| Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|